Clinical Trial

Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-08-17; most recent amendment 2025-01-24.
Status change: Not Yet Recruiting → Recruiting 2022-07-13
Trial Details
NCT Number NCT04520217
Lead Sponsor Wright State University
Conditions Photosensitivity, Microvesicle Particle
Enrollment 40 participants
Start Date 2022-06-06
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-27